A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Researchers have identified the transfer of mitochondria with mutated DNA from cancer cells to immune cells as a key ...

The immune system plays a key role in detecting and destroying cancer cells. Cancer immunotherapy works by programming immune ...

The immune system plays a key role in detecting and destroying cancer cells. Cancer immunotherapy works by programming immune cells to recognize and ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Researchers discovered that gut microbiota-derived hexa-acylated LPS enhances the effectiveness of anti-PD-1 cancer ...

A survey of the nation's oncologists showed that professional burnout has reached a new high (59% vs 45% in 2013), and fewer ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

Lunit and SITC collaborate to offer SITC members exclusive access to Lunit SCOPE IO for AI-driven tumor microenvironment analysis. SITC is the world's leading member-driven organization specifically ...

I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team,” stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance.